64Cu-NOTA-曲妥珠单抗的开发用于HER2靶向:一种药代动力学改善、可用于人体研究的放射性药物
本研究将曲妥珠单抗经SCN-Bn-NOTA偶联并标记64Cu,在HER2阳性乳腺癌BT-474移植瘤模型中行小动物PET显像与生物分布研究,并用基于图像的蒙特卡罗方法估算动物内照射剂量。结果显示标记产率高、放化纯度>98%,血清稳定性好、免疫活性好,BT-474肿瘤摄取在注射后48小时最高,心脏、肝脏、脾脏吸收剂量分别为0.048、0.079、0.047 mGy/MBq。
要点
- 64Cu-NOTA-曲妥珠单抗放化纯度>98%,血清稳定性高、免疫活性好。
- BT-474移植瘤模型中,注射后48小时肿瘤摄取最高。
- 心脏、肝脏、脾脏吸收剂量分别为0.048、0.079、0.047 mGy/MBq。
核心结论
- 64Cu-NOTA-曲妥珠单抗在体外和体内均有效靶向表达HER2的肿瘤,且因驻留时间短而吸收剂量相对较低。
- 作者认为64Cu-NOTA-曲妥珠单抗可用于为HER2治疗选择合适的患者和时机、监测HER2靶向治疗后的治疗反应以及检测远端或转移性播散。
研究设计与样本
- 本研究为放射性药物开发研究,将曲妥珠单抗与SCN-Bn-NOTA偶联并用64Cu标记。
- 检测了64Cu-NOTA-曲妥珠单抗的血清稳定性和免疫活性。
- 在HER2阳性乳腺癌BT-474移植瘤模型中进行了小动物PET显像和生物分布研究。
- 采用基于图像的方法结合蒙特卡罗N粒子代码确定实验动物的内照射剂量。
主要发现
- 64Cu-NOTA-曲妥珠单抗以高标记产率和放化纯度(>98%)制备,在血清中显示高稳定性并具有良好的免疫活性。
- PET显像和生物分布结果显示,BT-474肿瘤中64Cu-NOTA-曲妥珠单抗的摄取在注射后48小时最高。
- 在有和无BT-474肿瘤移植瘤的小鼠中,64Cu-NOTA-曲妥珠单抗的血液放射性浓度随时间呈双指数下降。
- 计算的64Cu-NOTA-曲妥珠单抗吸收剂量为心脏0.048 mGy/MBq、肝脏0.079 mGy/MBq、脾脏0.047 mGy/MBq。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The purpose of this study was to develop 64Cu-labeled trastuzumab with improved pharmacokinetics for human epidermal growth factor receptor 2 (HER2). Methods: Trastuzumab was conjugated with SCN-Bn-NOTA and radiolabeled with 64Cu. Serum stability and immunoreactivity of 64Cu-NOTA-trastuzumab were tested. Small-animal PET imaging and biodistribution studies were performed in a HER2-positive breast cancer xenograft model (BT-474). The internal dosimetry for experimental animals was determined using the image-based approach with the Monte Carlo N-particle code. Results:64Cu-NOTA-trastuzumab was prepared with high radiolabeling yield and radiochemical purity (>98%) and showed high stability in serum and good immunoreactivity. Uptake of 64Cu-NOTA-trastuzumab was highest at 48 h after injection as determined by PET imaging and biodistribution results in BT-474 tumors. The blood radioactivity concentrations of 64Cu-NOTA-trastuzumab decreased biexponentially with time in both mice with and mice without BT-474 tumor xenografts. The calculated absorbed dose of 64Cu-NOTA-trastuzumab was 0.048 mGy/MBq for the heart, 0.079 mGy/MBq for the liver, and 0.047 mGy/MBq for the spleen. Conclusion:64Cu-NOTA-trastuzumab was effectively targeted to the HER2-expressing tumor in vitro and in vivo, and it exhibited a relatively low absorbed dose due to a short residence time. Therefore, 64Cu-NOTA-trastuzumab could be applied to select the right patients and right timing for HER2 therapy, to monitor the treatment response after HER2-targeted therapy, and to detect distal or metastatic spread.
引用
- Woo SK, Jang SJ, Seo MJ, et al. Development of 64Cu-NOTA-Trastuzumab for HER2 Targeting: A Radiopharmaceutical with Improved Pharmacokinetics for Human Studies. J Nucl Med. 2018. PMID: 29777007. doi:10.2967/jnumed.118.210294
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。